Health Systems Seeks Insight on Increasing Biosimilar Adoption Rate
| Industry | Health System |
| Problem | A client was seeking data analysis to evaluate and forecast whether increasing their use of biosimilars would lower their cost of providing services across different lines of business. The client needed a financial model estimating if the switch to biosimilars would be beneficial across their health system. |
| PHSI Solution | PHSL used multiple processes to analyze and compare biosimilar data with innovator products. PHSL reviewed quarterly pricing changes, reimbursement models, and ASP value trends to provide an estimated model for the client to measure the impact of biosimilar adoption, which also considered the impact of rebates. |
| Results | PHSL’s projected model indicated that increasing biosimilar usage can be beneficial to the health system. The model gave the client insight by line of business where biosimilars could generate savings and assisted management to determine the future strategic direction. |
Poll Results
August 2023 Question of the Month
What steps do you take when learning about an electronic prescribing challenge?
Root cause analysis: 0%
Compendia review: 0%
Engage a partner: 0%
All of the above: 50%
None of the above: 50%
July 2023 Question of the Month
Does your organization have a strategy for Humira biosimilar launches?
Yes, well defined: 0%
We have a framework: 50%
Waiting for clarity: 0%
No: 0%
Unaware of need: 50%
June 2023 Question of the Month
How far in advance of NDA/BLA expected approval do (or should) manufacturers begin planning their compendia submission strategy?
During Phase II Trials: 0%
Initiation of Phase III Trials: 66%
6 months prior to approval: 33%
3 months prior to approval: 0%
At time of approval: 0%
After approval: 0%
No strategy: 0%
Contact
968 Perry Highway
Pittsburgh, PA 15237
Get Directions »
Phone: (412) 635-4650
Follow/Subscribe:
